HF
IKT icon

HRT Financial’s Inhibikase Therapeutics IKT Stock Holding History

HRT Financial’s Portfolio IKT Stock Details IKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-10,570
Closed -$21K – 4228
2025
Q4 		$21K Buy
+10,570
New +$16.8K ﹤0.01% 2979
2025
Q2 		– Sell
-65,906
Closed -$144K – 3071
2025
Q1 		$144K Buy
65,906
+19,490
+42% +$49K ﹤0.01% 2092
2024
Q4 		$150K Buy
+46,416
New +$116K ﹤0.01% 1996
2021
Q3 		– Sell
-2,500
Closed -$42K – 3487
2021
Q2 		$42K Buy
2,500
+564
+29% +$16.6K ﹤0.01% 2686
2021
Q1 		$69K Buy
+1,936
New +$78.4K ﹤0.01% 2502

Other funds holding IKT

SCV
Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $437M AUM
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

HRT Financial's IKT Position: Q1 2026 in Review

HRT Financial sold out of Inhibikase Therapeutics (IKT) in Q1 2026, closing a stake of 10,570 shares — an estimated $21K sold.

HRT Financial first reported a position in IKT in Q1 2021 and held it in 5 quarters. The position peaked at $150K in Q4 2024. 104 funds tracked by Wall St. Rank hold IKT as of Q1 2026.

  • HRT Financial reported no remaining Inhibikase Therapeutics position as of Q1 2026 after selling out during the quarter.
  • HRT Financial sold 10,570 Inhibikase Therapeutics shares in Q1 2026, an estimated $21K.
  • HRT Financial first reported a position in Inhibikase Therapeutics in Q1 2021 and held it in 5 quarters.
  • HRT Financial's Inhibikase Therapeutics position peaked at $150K in Q4 2024.
  • 104 funds tracked by Wall St. Rank held Inhibikase Therapeutics as of Q1 2026.

Based on HRT Financial's 13F filing for Q1 2026, filed 14 May 2026.